Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.



Credit: Susan Burghart

Fifty years ago, cannabis was known as the drug most emblematic of counterculture. Today, many people promote it as a fount of treatments for almost any ailment imaginable. This immense about-turn is reflected in changes in legal regimes: medicinal use of cannabis is now permitted in many countries, and some also allow the drug to be used recreationally. The times, they have a-changed.

No aspect of the cannabis journey better exemplifies its current status than the fortunes of cannabidiol. This cannabis extract has received regulatory approval in the United States for use in treating certain rare forms of childhood epilepsy. But cannabidiol is also often promoted, with little supporting evidence, as a general health elixir.

Numerous clinical trials that are investigating potential medical benefits of the many chemical components of cannabis are painting a promising picture, albeit one that is blurred by a lack of clarity over how the plant’s compounds interact. Researchers are also looking into the effects of combining cannabis consumption with exercise, after decades of positive anecdotal reports from athletes. But evidence of ill effects associated with cannabis use, including worrying correlations with mental illness, must be weighed against the drug’s possible medical value.

Legalization brings the benefits and burdens of operating a regulated industry. Cannabis growers are paying more heed to quality control and the environmental impact of cultivation. And genetic engineering is enabling researchers to optimize the cannabis plant for the mass production of pharmaceutical drugs. Meanwhile, policymakers who are seeking to integrate cannabis into society might need to rethink their approach.

We are pleased to acknowledge the financial support of Auxly Cannabis Group Inc. in producing this Outlook. As always, Nature retains sole responsibility for all editorial content.

Nature 572, S1 (2019)


This article is part of Nature Outlook: Cannabis, an editorially independent supplement produced with the financial support of third parties. About this content.


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links